(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 28 February 2002 (28.02.2002)

(10) International Publication Number WO 02/016559 A3

(51) International Patent Classification7: C12N 5/06, A01K 67/027, A61P 35/00

(21) International Application Number: PCT/EP01/09661

(22) International Filing Date: 21 August 2001 (21.08.2001)

(25) Filing Language: **English**

English (26) Publication Language:

(30) Priority Data:

22 August 2000 (22.08.2000) 09/643,508 US

(71) Applicant: THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(71) Applicant (for all designated States except AT): NOVAR-TIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basle (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor: YU, John; 8480 La Jolla Shores Drive, La Jolla, CA 92037 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report:

7 August 2003

(15) Information about Correction: **Previous Correction:**

see PCT Gazette No. 21/2002 of 23 May 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IN VIVO ANIMAL MODEL OF HUMAN LEUKEMIA

(57) Abstract: The present invention provides a process for making an in vivo model of human leukemia. The process includes the steps of: pre-conditioning an immunodeficient rodent by administering to the rodent a sub-lethal dose of irradiation and injecting the rodent with an effective pre-conditioning amount of human fetal cord blood mononuclear cells; maintaining the rodent for from about 5 to 10 days; and injecting the rodent with an effective engrafting amount of primary human leukemia cells. An in vivo and in vitro model of human leukemia are also provided.

ational Application No

rui/EP 01/09661 a. classification of subject matter IPC 7 C12N5/06 A01k A01K67/027 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 AO1K C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. STEELE J P C ET AL: "T-cell acute 1 - 17Υ lymphoblastic leukemia (T-ALL): Engraftment in SCID mice." BLOOD. vol. 86, no. 10 SUPPL. 1, 1995, page 782A XP002200448 37th Annual Meeting of the American Society of Hematology; Seattle, Washington, USA: December 1-5, 1995 ISSN: 0006-4971 page 2015, paragraph 1 -page 2016, paragraph 1 US 6 010 696 A (HAYNESWORTH STEPHEN E ET 1 - 17AL) 4 January 2000 (2000-01-04) abstract column 1, line 55 -column 3, line 30 Patent family members are listed in annex. Further documents are listed in the continuation of box C. χ ° Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docudocument referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 19 June 2002 07/08/2002 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Mateo Rosell, A.M.

ional Application No ドエレ/EP 01/09661

		PC1/EF 01/09001	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	neievant to cialiff No.	
А	STEELE JEREMY P C ET AL: "Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice." BLOOD, vol. 90, no. 5, 1997, pages 2015-2019, XP002200449 ISSN: 0006-4971 Abstract 3114	1-17	
Α	US 5 733 542 A (HAYNESWORTH STEPHEN E ET AL) 31 March 1998 (1998-03-31) the whole document	1	
P, X	DIALYNAS DENO P ET AL: "Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood." STEM CELLS (MIAMISBURG), vol. 19, no. 5, 2001, pages 443-452, XP002200450 ISSN: 1066-5099 the whole document	1-17	
P, X	DIALYNAS DENO P ET AL: "Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice." BLOOD, vol. 97, no. 10, 15 May 2001 (2001-05-15), pages 3218-3225, XP002200451 ISSN: 0006-4971 the whole document	1	
P,X	SHAO L ET AL: "Enhancement of human leukemia colony formation by factor(s) derived from bone marrow of NOD/scid mice reconstituted with human cord blood." BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), page 767a XP001073697 42nd Annual Meeting of the American Society of Hematology; San Francisco, California, USA; December 01-05, 2000 ISSN: 0006-4971 the whole document	1-17	

ional Application No

0.10 ::	AL A DOCUMENTO CONCIDENCE TO THE TAXABLE PROPERTY.	PC1/EP 01/09061		
	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	Indiana Land		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Р,Х	SHAO LI-EN ET AL: "Human cord blood conditioned medium enhances leukemia colony formation in vitro." LEUKEMIA RESEARCH, vol. 24, no. 12, December 2000 (2000-12), pages 1041-1048, XP002200452 ISSN: 0145-2126 the whole document	1-17		
E	WO 01 94541 A (SESHI BEERELLI ;UNIV SOUTH FLORIDA (US)) 13 December 2001 (2001-12-13) abstract page 6, line 14-20 page 17, line 9 -page 18, line 20			

Information on patent family members

pational Application No PTT/EP 01/09661

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
US 6010696	Α	04-01-2000	US	5733542 A	31-03-1998	
			US	5486359 A	23-01-1996	
			US	5226914 A	13-07-1993	
			US	5197985 A	30-03-1993	
			ΑU	4704196 A	14-08-1996	
			WO	9623058 A1	01-08-1996	
			US	6087113 A	11-07-2000	
			US	5811094 A	22-09-1998	
			US	5837539 A	17-11-1998	
			AU	669850 B2	27-06-1996	
			AU	2252492 A	12-01-1993	
			CA	2111845 A1	23-12-1992	
			EP	0592521 A1	20-04-1994	
			JP	7500001 T	05-01-1995	
			WO	9222584 A1	23-12-1992	
US 5733542	Α	31-03-1998	US	5486359 A	23-01-1996	
			US	5197985 A	30-03-1993	
			US	5226914 A	13-07-1993	
			ΑU	4704196 A	14-08-1996	
			US	6010696 A	04-01-2000	
			WO	9623058 A1	01-08-1996	
			US	6087113 A	11-07-2000	
			US	5811094 A	22-09-1998	
			US	5837539 A	17-11-1998	
			AU	669850 B2	27-06-1996	
			AU	2252492 A	12-01-1993	
			CA	2111845 A1	23-12-1992	
			EP	0592521 A1	20-04-1994	
			JP	7500001 T	05-01-1995	
			WO	9222584 A1	23-12-1992	
WO 0194541	Α	13-12-2001	AU	6476301 A	17-12-2001	
			WO	0194541 A2	13-12-2001	